23andMe considers sale as cash runs low

The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.

By Nick Paul Taylor • Jan. 30, 2025

Getinge exits surgical perfusion, creating opportunity for Livanova

Getinge CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced the company off the U.S. market in 2015.

By Nick Paul Taylor • Jan. 30, 2025

Stryker to sell spinal implants business

The company named a new CFO and shared an update on its planned Inari Medical acquisition.

By Elise Reuter • Jan. 29, 2025

Intuitive execs cast wary eye on potential Trump tariffs

The surgical robot leader is watching developments under the new administration but has not included any tariff impact in its financial forecast.

By Susan Kelly • Jan. 24, 2025

Abbott expects to launch first PFA device outside of the US this year

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

By Elise Reuter • Jan. 22, 2025

J&J coordinating with FDA on US pause of Varipulse due to safety risks

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will restart after halting procedures in early January.

By Ricky Zipp • Jan. 22, 2025

Trump’s return to office brings uncertainty for medtech industry

With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.

By Ricky Zipp • Dec. 18, 2024

Henry Schein to acquire medical supplier Acentus

Acentus, which specializes in supplying glucose sensors to patients’ homes, continues Henry Schein’s recent focus on building its homecare medical supplies business.

By Ricky Zipp • Nov. 21, 2024

Medtronic’s ablation sales slowed by PFA supply issues

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues that have now been resolved.

By Ricky Zipp • Nov. 19, 2024

Boston Scientific closes $3.7B Axonics deal after lengthy review

Boston Scientific announced the acquisition in January, but the review dragged on after the Federal Trade Commission requested more information.

By Ricky Zipp • Nov. 15, 2024

23andMe to lay off more than 200 employees amid business struggles

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”

By Ricky Zipp • Nov. 13, 2024

Baxter to restart second IV fluid production line at hurricane-damaged site

CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter from Hurricane Helene's disruption.

By Susan Kelly • Nov. 11, 2024

Exact Sciences’ forecast cut shocks analysts

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.

By Nick Paul Taylor • Nov. 8, 2024

Tandem, Insulet tout Type 2 expectations as tech attracts new users

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while Tandem plans to file a Type 2 submission by year’s end.

By Ricky Zipp • Nov. 8, 2024

Siemens Healthineers confident it can cope with Trump tariffs

CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump returns to the White House.

By Nick Paul Taylor • Nov. 7, 2024

Masimo, amid leadership transition, targets cost reductions

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not spun off.

By Susan Kelly • Nov. 6, 2024

Baxter, Medtronic, Insulet to wrap up medtech earnings

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation device.

By Elise Reuter • Nov. 5, 2024

Integra Lifesciences names Mojdeh Poul as CEO

Poul will take over the company in January after spending 11 years with 3M and working at Medtronic and Boston Scientific.

By Nick Paul Taylor • Nov. 5, 2024

Stryker, Zimmer outline different M&A strategies

Stryker CEO Kevin Lobo told investors M&A will be the “number one use of our cash going forward,” while Zimmer Biomet CEO Ivan Tornos emphasized internal product development for growth.

By Elise Reuter • Oct. 30, 2024

Philips cuts sales forecast after ‘significant deterioration’ in China

CEO Roy Jakobs expects the slump to continue into 2025, driven by China’s anti-corruption measures.

By Nick Paul Taylor • Oct. 28, 2024

Dexcom chief commercial officer to retire

Teri Lawver is leaving the diabetes tech company during a challenging time, with sales slowing after a workforce restructuring.

By Elise Reuter • Oct. 25, 2024

Edwards’ TAVR sales faced ongoing hospital constraints in Q3

Hurt by a slowdown in procedures for its heart valve replacement devices, Edwards said it is working with hospitals to manage workflow challenges.

By Susan Kelly • Oct. 25, 2024

Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared to a year ago.

By Susan Kelly • Oct. 23, 2024

Intuitive readies da Vinci 5 for broader launch after placing 110 robots in Q3

BTIG analysts wrote that installations of Intuitive’s new robotic surgery system are “well ahead of lofty” expectations.

By Susan Kelly • Oct. 18, 2024

Abbott CEO sees ‘mass market potential’ for CGMs

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

By Ricky Zipp • Oct. 16, 2024